ArticleWorld journal of stem cells2026
Epiregulin enhances periodontal tissue regeneration by promoting bone marrow mesenchymal stem cell functions under inflammatory niches.
Article in World journal of stem cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Quiescent tumor cells shape the immunosuppressive microenvironment in pancreatic cancer.Nature communications · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMesenchymal stem cells are promising regenerative therapies; however, inflammation often impairs their function. Epiregulin (EREG), a member of the epidermal growth factor family, regulates cell migration, differentiation, and tissue repair. However, its effects on periodontal tissue regeneration using mouse bone marrow stem cells (mBMSCs) under inflammatory conditions remain unclear. We hypothesized that EREG activates epidermal growth factor receptor (EGFR)-extracellular signal-regulated kinase 1/2 (ERK1/2) in inflammatory conditions to improve mBMSC function and periodontitis treatment results.
aimTo investigate EREG's role in periodontal tissue regeneration, aiming to identify therapeutic targets for periodontal treatment.
methodsTumor necrosis factor alpha stimulates inflammation. Lentiviral short hairpin RNA inhibited EGFR expression. Scratch wounds, Transwell assays, Alizarin Red staining, and Western blotting were used to assess the effects and mechanisms of EREG on the migration, chemotaxis, and osteogenic differentiation capacity of mBMSCs. Micro-computed tomography and histological staining evaluated periodontal tissue regeneration.
resultsEREG enhances the migration, chemotaxis, and osteogenic differentiation of mBMSCs under inflammatory conditions. Mechanistically, EREG binds to EGFR and activates the ERK1/2 signaling pathway to stimulate these functions. Local administration of EREG facilitated periodontal tissue regeneration in a rat model of periodontitis.
conclusionEREG promotes mBMSC function
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.